Type I insulin-like growth factor receptor (IGF-IR) is a transmembrane receptor tyrosine kinase that is widely expressed in many cell lines and cell types within fetal and postnatal tissues. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis.
Background References
1. Chen Y et al. Exercise-Induced Reduction of IGF1R Sumoylation Attenuates Neuroinflammation in APP/PS1 Transgenic Mice. J Adv Res. 2025 Mar
2. Fang K et al. Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia. J Exp Clin Cancer Res. 2023 Mar
Western blot analysis of IGF1R on different lysates with Rabbit anti-IGF1R antibody (HA724644) at 1/20,000 dilution.
Lane 1: MCF7 (Human breast cancer cell) cell lysate
Lane 2: HeLa (Human cervical adenocarcinoma cell) cell lysate
Lane 3: HepG2 (Human hepatocellular carcinoma cell) cell lysate
Lane 4: A431 (Human epidermoid carcinoma skin squamous cell) cell lysate
Lane 5: C2C12 (Mouse myoblast) cell lysate
Lane 6: NIH/3T3 (Mouse fibroblast) cell lysate
Lane 7: C6 (Rat glioma cell) cell lysate
The expression profile observed is consistent with what has been described in the literature (PMID: 11402025).
Lysates/proteins at 15 µg/Lane.
Exposure time: 25 seconds; ECL: K1801
Blocking: 5% NFDM/TBST, 1 hour at room temperature
Primary antibody: HA724644, 1/20,000 in primary antibody dilution buffer (K1803), overnight at 4 °C
Secondary antibody: Goat anti-Rabbit IgG-HRP (HA1001), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature
Predicted band size: 155 kDa
Observed band size: 100/200 kDa
Western blot analysis of IGF1R on different lysates with Rabbit anti-IGF1R antibody (HA724644) at 1/5,000 dilution.
Lane 1: Mouse brain tissue lysate
Lane 2: Mouse spleen tissue lysate
Lane 3: Rat brain tissue lysate
The expression profile observed is consistent with what has been described in the literature (PMID: 11402025).
Lysates/proteins at 30 µg/Lane.
Exposure time: 1 minute; ECL: K1801
Blocking: 5% NFDM/TBST, 1 hour at room temperature
Primary antibody: HA724644, 1/5,000 in primary antibody dilution buffer (K1803), overnight at 4 °C
Secondary antibody: Goat anti-Rabbit IgG-HRP (HA1001), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature
Predicted band size: 155 kDa
Observed band size: 100/200 kDa
Application: Immunocytochemistry (IF-cell)
Species: Human
Sample: MCF7 (Human breast cancer cell)
Fixation: 4% Paraformaldehyde, 15 minutes at room temperature.
Permeabilization: 0.1% Triton X-100, 15 minutes at room temperature.
Blocking: 1% BSA + 10% normal goat serum, 1 hour at room temperature.
Antibody dilution buffer: 1% BSA in PBST.
Primary antibody: HA724644, 1/200, overnight at 4°C.
Secondary antibody: Goat Anti-Rabbit IgG (iFluor™ 488, HA1121), 45 minutes at room temperature.
Counterstain: Beta tubulin (HA601187, Red), 1/100, overnight at 4℃. The nuclear counterstain was DAPI (Blue).
Application: Immunohistochemistry (IHC-P)
Species: Human
Tissue: Bronchus
Sample: Paraffin-embedded section